Buy Pentasa

Pentasa

Pentasa: Overview of the Mesalamine Pill for Digestive Health

Introduction

Pentasa is a brand-name medication that contains the active ingredient mesalamine. It is formulated as a 400 mg oral pill and is classified under the therapeutic category of digestive health. In Hong Kong, Pentasa is a prescription product regulated by the Pharmacy and Poisons Board of the Department of Health. The medication is primarily used to manage inflammatory conditions of the lower gastrointestinal tract.

How Pentasa Works in the Body

Mesalamine belongs to the class of 5-aminosalicylic acid (5-ASA) compounds. After oral ingestion, the coating of Pentasa releases mesalamine throughout the small and large intestines, allowing the drug to act locally on inflamed mucosa. The primary mechanisms include:

• Inhibition of cyclooxygenase and lipoxygenase pathways, which reduces the production of prostaglandins and leukotrienes-key mediators of inflammation.
• Scavenging of free radicals, thereby limiting oxidative tissue damage.
• Modulation of nuclear factor-κB (NF-κB) activity, leading to decreased transcription of inflammatory cytokines.

These actions collectively dampen the inflammatory response in the colon, helping to achieve symptom relief and mucosal healing. The onset of effect generally occurs within a few days, while the full therapeutic benefit may be seen after several weeks of continuous therapy.

Conditions Treated by Pentago

Pentasa is approved in Hong Kong for the following indications:

• Ulcerative colitis (induction of remission and maintenance therapy) in adult patients.
• Crohn’s disease involving the ileum and right colon, where the drug’s release profile allows delivery to the terminal ileum.

The medication is intended for adults; pediatric use follows specific dosing recommendations provided by the prescribing physician.

Patient Suitability and Contraindications

Who Should Use Pentasa?

• Adults diagnosed with ulcerative colitis or ileal Crohn’s disease who require anti-inflammatory therapy.
• Patients who can swallow whole tablets and have no known hypersensitivity to mesalamine or any component of the formulation.

Absolute Contraindications

• Documented hypersensitivity to mesalamine, sulfonamides, or any excipient in the pill.
• Severe hepatic impairment (Child-Pugh class C) where drug metabolism may be markedly altered.
• Known or suspected obstruction of the gastrointestinal tract that could prevent proper drug distribution.

Relative Contraindications

• Moderate renal impairment (creatinine clearance 30-50 mL/min); dose adjustment may be needed.
• Pregnancy (especially the third trimester) and lactation; benefits must be weighed against potential fetal or neonatal risks.
• Concurrent use of non-steroidal anti-inflammatory drugs (NSAIDs) that may increase gastrointestinal irritation.

Special Populations

• Elderly: May have reduced renal function; monitor kidney parameters periodically.
• Pregnancy & Breastfeeding: Discuss risks and benefits with a qualified healthcare professional before initiation.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Nausea, abdominal pain, or mild diarrhea (often transient during treatment initiation).
• Headache or dizziness.
• Skin rash or mild photosensitivity.

Serious Adverse Events

• Severe allergic reactions (e.g., anaphylaxis, Stevens-Johnson syndrome) requiring immediate medical attention.
• Acute pancreatitis, characterized by persistent abdominal pain radiating to the back, nausea, and elevated pancreatic enzymes.
• Renal function deterioration, especially in patients with pre-existing kidney disease.

Drug Interactions

• Major: Concomitant use with high-dose NSAIDs can increase the risk of renal impairment.
• Moderate: Antacids containing magnesium or aluminum may affect the dissolution of certain mesalamine formulations, though Pentasa’s coating is designed to mitigate this effect.
• CYP Interaction: Mesalamine is not a significant substrate of cytochrome P450 enzymes; therefore, most enzyme-inducing or inhibiting drugs have minimal impact.

Food and Lifestyle Interactions

• Pentasa should be taken with a full glass of water; food does not notably affect absorption.
• Alcohol consumption does not directly interact with mesalamine but excessive drinking may exacerbate gastrointestinal symptoms.
• No specific restrictions on driving or operating machinery, unless side effects like dizziness occur.

How to Take Pentasa

• Standard dosing: The typical regimen for ulcerative colitis starts with 400 mg taken two to three times daily (total daily dose 800-1200 mg), with the possibility of titrating up to a maximum of 2.4 g per day based on disease severity and response.
• Crohn’s disease: Dosing often begins at 800 mg daily, divided into two doses, with adjustments as needed.
• Administration: Swallow each 400 mg tablet whole; do not crush, chew, or split the pill, as this may alter the targeted release of mesalamine.
• Missed dose: Take the missed dose as soon as remembered if it is at least 4 hours before the next scheduled dose; otherwise, skip the missed dose and continue the regular schedule. Do not double the dose.
• Overdose: Signs may include severe nausea, vomiting, abdominal pain, and diarrhea. Seek emergency medical care; there is no specific antidote, and treatment is supportive.
• Discontinuation: Abrupt cessation can lead to disease flare-ups. Discuss tapering strategies with a healthcare provider if long-term therapy is being considered.

Monitoring and Follow-Up

Regular monitoring helps ensure safety and effectiveness:

• Renal function: Serum creatinine and estimated glomerular filtration rate (eGFR) at baseline and periodically (e.g., every 6-12 months) or sooner if symptoms emerge.
• Liver enzymes: Check ALT/AST levels at baseline and during therapy, especially in patients with pre-existing hepatic disease.
• Disease activity: Clinical assessment of bowel habits, abdominal pain, and rectal bleeding; colonoscopic evaluation may be performed to document mucosal healing.
• Electrolytes: Monitor for electrolyte disturbances in patients experiencing persistent diarrhea.

Patients should contact their healthcare professional promptly if they notice new or worsening symptoms such as severe abdominal pain, blood in stool, or signs of an allergic reaction.

Storage and Handling

• Keep Pentasa tablets at room temperature (≤ 25 °C) away from excessive heat, humidity, and direct sunlight.
• Store in the original container with the child-proof cap securely closed.
• Do not use the medication after the expiration date printed on the package.
• Dispose of unused tablets according to local pharmacy guidelines or return them to a medication take-back program.

Medication-Specific Glossary

5-ASA (5-Aminosalicylic Acid)

The class of compounds, including mesalamine, that exert anti-inflammatory effects directly on the intestinal mucosa.

Mucosal Healing

The restoration of the intestinal lining’s normal architecture, a key therapeutic goal in inflammatory bowel disease.

Induction Therapy

An initial treatment phase aimed at achieving remission of active disease symptoms.

Maintenance Therapy

Ongoing treatment to prevent relapse after remission has been attained.

Medical Disclaimer

This article provides educational information about Pentasa and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.